Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates

Marwa G. El-GazzarDepartment of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt; Correspondence[email protected]

Nessma H. NafieDepartment of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt;

Alessio NocentiniNEUROFARBA Department, Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Firenze, Italy

Mostafa M. GhorabDepartment of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt;

Helmi I. HeibaDepartment of Drug Radiation Research, National Center for Radiation Research and Technology (NCRRT), Egyptian Atomic Energy Authority (EAEA), Cairo, Egypt;

Claudiu T. SupuranNEUROFARBA Department, Pharmaceutical and Nutraceutical Sciences Section, University of Florence, Firenze, ItalyCorrespondence[email protected]

http://orcid.org/0000-0003-4262-0323

Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates

Table 2. Percentage growth inhibition (GI%) of in vitro human tumour cell lines at 10 µM concentration for ten compounds.

Table 1. Inhibition data of human CA isoforms hCA I, II, IV and IX with compounds 2–21 reported here and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow CO₂ hydrase assay.

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Carbonic anhydrase inhibition with a series of novel benzenesulfonamide-triazole conjugates

Figures & data

Table 2. Percentage growth inhibition (GI%) of in vitro human tumour cell lines at 10 µM concentration for ten compounds.

Table 1. Inhibition data of human CA isoforms hCA I, II, IV and IX with compounds 2–21 reported here and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow CO2 hydrase assay.

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Table 1. Inhibition data of human CA isoforms hCA I, II, IV and IX with compounds 2–21 reported here and the standard sulfonamide inhibitor acetazolamide (AAZ) by a stopped flow CO₂ hydrase assay.